Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status 

In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting

However, regulatory and financial issues will shape when and where this happens  

Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required 

AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung

Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.

An exploratory analysis from the IMpower010 trial adds support to the use of post-chemotherapy adjuvant immunotherapy for selected early stage non-small-cell lung cancer

Results from the ATALANTE-1 and MRTX-500 trials show efficacy improvements with immunotherapy in patients post-immune checkpoint inhibitor failure

Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib

Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years